Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Amgn crawled date : 2022 - 09 - 12 save search
AMGEN ANNOUNCES WEBCAST OF 2022 BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
Published: 2022-09-12 (Crawled : 22:00) - biospace.com/
AMGN | $262.75 -0.5% -0.49% 1.4M
|
Health Technology
|
| O: -3.91%
H: 1.55%
C: -0.16%
america global conference
Entera Bio to Present at H.C. Wainwright 24th Annual Global Investment Conference
Published: 2022-09-12 (Crawled : 21:00) - globenewswire.com
ENTX | $2.24 0.9% 1.33% 170K
|
Health Technology
|
| O: 0.71%
H: 0.72%
C: -1.42%
AMGN | $262.75 -0.5% -0.49% 1.4M
|
Health Technology
|
| O: -0.25%
H: 0.05%
C: -4.29%
global conference
Entera Bio Presents Dose Proportional Absorption and Correlation to BMD Clinical Response Data from its Phase 2 Study of EB613 in Post-Menopausal Osteoporosis Patients at the ASBMR 2022 Annual Meeting
Published: 2022-09-12 (Crawled : 11:00) - globenewswire.com
ENTX | $2.24 0.9% 1.33% 170K
|
Health Technology
|
| O: 0.72%
H: 6.43%
C: 0.0%
AMGN | $262.75 -0.5% -0.49% 1.4M
|
Health Technology
|
| O: -3.91%
H: 1.55%
C: -0.16%
eb613 correlation meeting response study osteoporosis
LUMAKRAS® (SOTORASIB) COMBINED WITH VECTIBIX® (PANITUMUMAB) SHOWS CONFIRMED 30% OBJECTIVE RESPONSE RATE IN PATIENTS WITH KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER
Published: 2022-09-12 (Crawled : 09:00) - prnewswire.com
MS | News 0 d | $90.26 0.2% -0.31% 5.1M
|
Finance
|
| O: 0.6%
H: 1.16%
C: 0.17%
CCXI | $51.99 -0.04%
|
Health Technology
|
| O: -0.16%
H: 0.16%
C: 0.06%
BGNE | $131.96 0.08% 0.06% 110K
|
Health Technology
|
| O: -1.88%
H: 3.78%
C: 3.73%
AMGN | $262.75 -0.5% -0.49% 1.4M
|
Health Technology
|
| O: -3.91%
H: 1.55%
C: -0.16%
lumakras response cancer
Celiac Diseases Drugs Market Report by Technavio expects growth to accelerate at 16.95% CAGR
Published: 2022-09-12 (Crawled : 08:00) - prnewswire.com
GLAXF | $20.2 0.65% -14.18% 40
|
Health Technology
|
| O: -4.56%
H: 9.43%
C: 7.62%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.78%
H: 0.58%
C: 0.58%
GSK | $39.27 -0.83% 0.26% 1.9M
|
Health Technology
|
| O: 1.44%
H: 1.67%
C: 0.31%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: 0.0%
BLRX | $0.6401 3.01% 3.07% 300K
|
Health Technology
|
| O: -3.3%
H: 1.7%
C: -6.82%
AMGN | $262.75 -0.5% -0.49% 1.4M
|
Health Technology
|
| O: -3.91%
H: 1.55%
C: -0.16%
report growth market
LUMAKRAS®/LUMYKRAS® (SOTORASIB) DEMONSTRATES SUPERIOR PROGRESSION-FREE SURVIVAL OVER DOCETAXEL IN FIRST POSITIVE PHASE 3 TRIAL OF A KRAS G12C INHIBITOR IN NON-SMALL CELL LUNG CANCER
Published: 2022-09-11 (Crawled : 00:00) - prnewswire.com
MS | News 0 d | $90.26 0.2% -0.31% 5.1M
|
Finance
|
| O: 0.6%
H: 1.16%
C: 0.17%
CCXI | $51.99 -0.04%
|
Health Technology
|
| O: -0.16%
H: 0.16%
C: 0.06%
BGNE | $131.96 0.08% 0.06% 110K
|
Health Technology
|
| O: -1.88%
H: 3.78%
C: 3.73%
AMGN | $262.75 -0.5% -0.49% 1.4M
|
Health Technology
|
| O: -3.91%
H: 1.55%
C: -0.16%
lumakras lung trial positive cancer
Gainers vs Losers
| 60% | 40% |
Top 10 Gainers
AGBA | News | $1.03 157.5% 57.94% 120M
|
Finance
ZCMD | $1.45 5.84% 52.1% 2.3M
|
Commercial Services
INVO | $1.52 100.0% 51.13% 5M
|
Health Technology
ISPC | $0.421 97.65% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.5 45.65% 470K
|
OST | $0.509 23.81% 45.26% 90K
|
GDHG | $0.263 21.76% 40.66% 3.1M
|
XPON | News | $3.15 63.21% 37.74% 16M
|
TIRX | $0.8 65.02% 30.74% 58M
|
BNTC | News | $6.82 42.08% 30.64% 3.5M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.